Akademik Veri Yönetim Sistemi
Turkish Journal of Medical Sciences, cilt.25, sa.3, ss.183-186, 1995 (Scopus)
The effect of inhaled budesonide (BUD) on adrenal function and lipid metabolism was evaluated in 20 patients with bronchial asthma. The trail was designed as a prospective, randomized study of the effect of BUD in daily doses of 800 and 1600 μg in two parallel periods of 4 weeks. The 24 hr urinary free cortisol, single serum cortisol (8:00 am), serum triglyceride, cholesterol and high density lipoprotein (HDL)-cholesterol were measured before and after the study period. No significant (p > 0.05) changes were found in any of these parameters in a daily dose of 800 μg. Compared to baseline, 1600 μg daily BUD significantly reduced the mean morning cortisol concentrations from 17.08 ± 4.11 to 10.75 ± 4.59 μg/dl (p < 0.01), and urinary free cortisol concentration from 37.72 ± 22.02 to 16.45 ± 10.92 μg/24 hr (p < 0.001). Furthermore, there were significant (p < 0.05) increase in serum cholesterol (from 206.91 ± 43.02 to 252.00 ± 62.30 mg/dl) and HDL-cholesterol (from 36.54 ± 6.28 to 45.27 ± 9.66 mg/dl) but the values were still within normal range. Triglyceride concentrations were unchanged in this group (136.09 ± 43.02; 169.45 ± 60.15 mg/dl)(p < 0.05). Thus, administration of this medication in recommended dosages was demonstrated to avoid significant systemic side effects.